CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
CureVac (Nasdaq: CVAC) has announced it will release its third quarter and first nine months 2024 financial results on November 12, 2024. The company will host a conference call and webcast at 3 p.m. CET / 9 a.m. EST on the same day. The event will include financial results presentation and business updates. Investors can access the webcast through CureVac's website, where presentation slides will be available before the event, and a replay will be provided afterward.
CureVac (Nasdaq: CVAC) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre e dei primi nove mesi del 2024 il 12 novembre 2024. L'azienda ospiterà una call di conferenza e un webcast alle 15:00 CET / 9:00 EST dello stesso giorno. L'evento includerà la presentazione dei risultati finanziari e aggiornamenti aziendali. Gli investitori possono accedere al webcast tramite il sito web di CureVac, dove le diapositive della presentazione saranno disponibili prima dell'evento, e una registrazione sarà fornita successivamente.
CureVac (Nasdaq: CVAC) ha anunciado que publicará sus resultados financieros del tercer trimestre y de los primeros nueve meses de 2024 el 12 de noviembre de 2024. La compañía llevará a cabo una llamada de conferencia y un webcast a las 3 p.m. CET / 9 a.m. EST el mismo día. El evento incluirá la presentación de resultados financieros y actualizaciones empresariales. Los inversores pueden acceder al webcast a través del sitio web de CureVac, donde las diapositivas de la presentación estarán disponibles antes del evento, y se proporcionará una grabación posteriormente.
CureVac (Nasdaq: CVAC)는 2024년 11월 12일 2024년 3분기 및 지난 9개월간의 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 3시 CET / 오전 9시 EST에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 이 이벤트에서는 재무 결과 발표와 비즈니스 업데이트가 포함될 것입니다. 투자자들은 CureVac의 웹사이트를 통해 웹캐스트에 액세스할 수 있으며, 슬라이드는 이벤트 전 미리 제공되며, 이후 다시 볼 수 있는 녹화도 제공될 것입니다.
CureVac (Nasdaq: CVAC) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre et des neuf premiers mois de 2024 le 12 novembre 2024. L'entreprise tiendra une conférence téléphonique et un webcast à 15h00 CET / 9h00 EST le même jour. L'événement comprendra une présentation des résultats financiers et des mises à jour commerciales. Les investisseurs peuvent accéder au webcast via le site web de CureVac, où les diapositives de présentation seront disponibles avant l'événement, et un replay sera fourni par la suite.
CureVac (Nasdaq: CVAC) hat angekündigt, dass es am 12. November 2024 seine Finanzergebnisse für das dritte Quartal und die ersten neun Monate 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 15:00 Uhr CET / 9:00 Uhr EST eine Telefonkonferenz und ein Webcast veranstalten. Die Veranstaltung umfasst die Präsentation der Finanzergebnisse und Unternehmensaktualisierungen. Investoren können über die Website von CureVac auf den Webcast zugreifen, wo die Präsentationsfolien vor der Veranstaltung verfügbar sein werden, und eine Aufzeichnung wird anschließend bereitgestellt.
- None.
- None.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at
3 p.m. CET / 9 a.m. EST.
Dial-in numbers to participate in the conference call:
U.S. Toll-Free: +1-877-407-0989
International: +1-201-389-0921
Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)
The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/
Corresponding presentation slides will be posted shortly before the start of the webcast. A replay will be made available at this website after the event.
About CureVac
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements of CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (the "SEC"). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
SOURCE: CureVac
View the original press release on accesswire.com
FAQ
When will CureVac (CVAC) report Q3 2024 earnings?
What time is CureVac's (CVAC) Q3 2024 earnings call?